Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity
Key Points
Tumor response to neoadjuvant therapy significantly varies among patients, highlighting the complexity of treatment outcomes.
Key evidence includes variation in HER2 expression levels found in pathology reports, with implications for therapeutic strategies.
Analysis of pathological evaluation reveals HER2 heterogeneity is a critical factor influencing treatment response.
Findings suggest a need for personalized approaches in managing HER2-positive breast cancer, as existing treatments may not be universally effective.
Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity | Synapse